Cyclosporine and nonsteroidal antiinflammatory drugs: Exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis

Journal of Clinical Pharmacology

Volumn 37, Issue 4, 1997, Pages 336-343

  Kovarik, J M ^a,c   Mueller, E A ^a   Gerbeau, C ^b   Tarral, A ^b   Francheteau, P ^b   Guerret, M ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Sandoz Pharma Ltd ^*

^c Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; DICLOFENAC; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSFORMATION; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; RHEUMATOID ARTHRITIS;

EID: 0030892211     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04311.x     Document Type: Article

References (27)

1. Ward JR: Earlier intervention with second line therapies. J Rheumatol 1990; 17(suppl):18-23.
2. Wilske KR, Healey LA: Remodelling the pyramid: a concept whose time has come. J Rheumatol 1989; 16:65-67.
3. Cash JM, Klippel JH: Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330;1368-1375.
4. Tugwell P: Cyclosporine in rheumatoid arthritis: documented efficacy and safety. Semin Arthritis Rheum 1992; (suppl)21:30-8.
5. Dijkmans BA, van Rijthoven AW, Goei Thé HS, et al: Cyclosporine in rheumatoid arthritis. Semin Arthritis Rheum 1992; 22:30-36.
6. Førre Ø: Cyclosporine in rheumatoid arthritis: an overview. Clin Rheumatol 1995; (suppl)14:33-36.
7. Yocum DE, Torley H: Cyclosporine in rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21:835-844.
8. International consensus report: the use of cyclosporin A in rheumatoid arthritis. Br J Rheumatol 1993; 32(suppl):1-3.
9. Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A:. Enhancement of cyclosporin A nephrotoxicity by diclofenac (letter). Clin Nephrol 1987; 27:213-214.
10. Harris KP, Jenkins D, Walls J: Nonsteroidal antiinflammatory drugs and cyclosporin: a potentially serious adverse interaction (letter). Transplantation 1988; 46:598-599.
11. Branthwaite JP, Nicholls A: Cyclosporin and diclofenac interaction in rheumatoid arthritis (letter). Lancet 1991; 337:252.
12. Mueller EA, Kovarik JM, Koelle EU, Merdjan H, Johnston A, Hitzenberger G: Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration. J Clin Pharmacol 1993; 33:936-943.
13. Kovarik JM, Mueller EA, Gaber M, Johnston A, Jähnchen E: Pharmacokinetics of cyclosporine and steady-state aspirin during coadministration. J Clin Pharmacol 1993; 33:513-521.
14. Kovarik JM, Kurki P, Mueller EA, Guerret M, Markert E, Alten R, et al: Diclofenac combined with cyclosporine in treatment-refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction. J Rheumatol 1996; 23:2033-2038.
15. Leeman TD, Transon C, Bonnabry P, Dayer P: A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exptl Clin Res 1993; 19:189-195.
16. Hubert P, Renson M, Crommen J: A fully automated high-performance liquid chromatographic method for determination of indomethacin in plasma. J Pharm Biomed Anal 1989; 7:1819-1827.
17. Toomey TM, Bartolucci SR, Hobbs DC: Analysis of piroxicam in plasma by high-performance liquid chromatography. J Chromatogr 1980; 183:104-108.
18. Steinijans VW, Hartman M, Huber R, Radtke HW: Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991; 29:323-328.
19. Alvan G, Orme M, Bertilsson L, Ekstrand R, Palmer R: Pharmacokinetics of indomethacin. Clin Pharmacol Ther 1975; 18:364-373.
20. McElnay JC, Passmore AP, Crawford VL, McConnell JG, Taylor IC, Walker FS: Steady state pharmacokinetic profile of indomethacin in elderly patients and young volunteers. Eur J Clin Pharmacol 1992; 43:77-80.
21. Fourtillon JB, Dubourg D: Pharmacokinetics of piroxicam with multiple dosing: comparison between two dosage regimens. In, Royal Society of Medicine International Congress and Symposium Series. The Rheumatological Disease Process: Focus on Piroxicam. London: Royal Society of Medicine, 1984; 67:85-89.
22. Langloh N: Experience with piroxicam in general practice: results of a German multicenter study on 18,888 patients. Eur J Rheumatol Inflamm 1983; 6:84-89.
23. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Mauel P: Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Disposit 1990; 18:595-606.
24. Todd PA, Sorkin EM: Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35:244-285.
25. Verbeeck RK, Blackburn JL, Loewen GR: Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1983; 8:297-331.
26. Altman RD, Perez GO, Sfakianakis GN: Interaction of cyclosporine A and nonsteroidal antiinflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992; 93:396-402.
27. Sturrock NDC, Lang CC, Struthers AD: Indomethacin and cyclosporin together produce marked renal vasoconstriction in humans. J Hypertension 1994; 12:919-924.